Idiopathic Hypersomnia (IH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
-1.jpg)
Idiopathic hypersomnia (IH) is a chronic neurologic disorder that manifests as pathologic daytime sleepiness with or without prolonged sleep durations. Population-based estimates of the frequency of IH are difficult to obtain, given the requirements for electrophysiologic testing and ruling out other disorders that may cause similar symptoms. Clinic-based estimates of IH prevalence are limited by differing referral patterns and biases, such that estimates of the relative frequency of IH to narcolepsy with cataplexy vary substantially, anywhere from 1:10 to greater than 1:1. Family history of excessive sleepiness, IH, or another central disorder of hypersomnolence is seen in 34–38% of IH patients, with parent-child transmission suggested by the finding that 12.5% of IH patients have at least one parent who routinely sleeps more than 9.5 hours per night.
·
Clinical features of IH and narcolepsy type 1
(NT1) are fairly distinct: patients with IH do not have cataplexy, while
patients with NT1 do; patients with IH have high sleep efficiency with few
nocturnal awakenings, while patients with NT1 have fragmented nocturnal sleep;
patients with IH have long and unrefreshing naps, while patients with NT1
generally find short naps to be restorative.
·
Diagnosis is complex, starting with
documenting the excess of night daytime sleep. Definitive diagnosis is based on
polysomnography completed with multiple sleep latency tests (MSLT), performed
without any medication with an effect on sleep.
Thelansis’s “Idiopathic Hypersomnia
(IH) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Idiopathic
Hypersomnia (IH) treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Idiopathic Hypersomnia (IH) across 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Idiopathic Hypersomnia (IH) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment